AZ COPD drug fails to match GSK rival after disappointing launch
FDA due to make decision in September
AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.
GSK also hopes to get IL-5 drug approved in COPD
GSK is aiming to revive its respiratory drugs franchise